Nevirapine and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nevirapine
Buprenorphine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Opioid withdrawal symptoms may occur with concomitant use of buprenorphine and a CYP3A4 inducer due to decreased plasma concentrations of buprenorphine. If use of a CYP3A4 inducer is necessary in a patient receiving buprenorphine, consider increasing the dose of buprenorphine until stable drug effects are achieved and monitor for withdrawal. When discontinuing a CYP3A4 inducer in a patient receiving buprenorphine therapy, consider a buprenorphine dose reduction and monitor for respiratory depression1. If the dosage cannot be adjusted in the absence of the CYP3A4 inducer, transition the patient back to a formulation of buprenorphine that permits more precise dose adjustments. In patients converted from a regimen of transmucosal buprenorphine coadministered with CYP3A4 inducers, monitor to ensure that the plasma buprenorphine level provided by subQ buprenorphine is adequate. In patients already on subQ buprenorphine who require a CYP3A4 inducer, monitor for withdrawal. If the dose of buprenorphine is not adequate in the presence of the concomitant medication, and the concomitant medication cannot be reduced or discontinued, adjust the dose of buprenorphine. If available doses do not permit achievement of the desired dose treat the patient with a formulation of buprenorphine that permits more precise dose adjustments 2.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
Literature reports
1 report — tap to read
a) The effects of coadministered CYP3A4 inducer on buprenorphine exposure in subjects treated with subQ buprenorphine have not been studied; however, such interactions have been established in studies using transmucosal buprenorphine. The effects of buprenorphine may be dependent on the route of administration 2.
Common questions
Can I take Nevirapine and Buprenorphine together?
Reduced buprenorphine exposure and reduced efficacy of buprenorphine Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nevirapine and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Nevirapine or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
Keep reading about Nevirapine
Keep reading about Buprenorphine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist